Abstract
The Pre-clinical Stage Partnering Agreements in Biopharma report detailed
understanding and analysis of how and why companies enter pre-clinical stage
licensing/business development and other forms of partnering arrangement.
The report provides a detailed understanding and analysis of how and why
companies enter pre-clinical stage licensing/business development and other
forms of partnering arrangement.
The focus of the report is on partnerships for pre-clinical stage compounds
where partners have joined forces to exploit these early stage opportunities.
This is an early stage of partnering undertaken by commercial entities with
the objective of utilizing lead molecules and pre-clinical compounds to
progress into clinical stage pipeline development.
The report provides access to average pre-clinical stage deal payment terms as
announced between the parties. This data provides useful insight into the
average and range of payments for upfront, milestone and royalty payments
agreed for pre-clinical stage deals.
This report contains over 800 links to online copies of actual pre-clinical
stage contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners.
The initial chapters of this report provide an orientation of pre-clinical
stage dealmaking and business activities. Chapter 1 provides an introduction
to the report, whilst chapter 2 provides an analysis of the trends in
pre-clinical stage partnering as well as a discussion on the merits and
attributes of dealmaking at the pre-clinical stage of development.
Chapter 3 provides an overview of the structure of pre-clinical stage
partnering deal contracts. The chapter includes numerous case studies to
enable understanding of pre-clinical stage partnering deals.
Chapter 4 provides a review of the leading pre-clinical stage partnering deals
since 2000. Deals are listed by headline value, signed by bigpharma, most
active bigpharma, and most active of all biopharma companies. Where the deal
has an agreement contract published at the SEC a link provides online access
to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of pre-clinical stage
contract documents available in the public domain. Each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all pre-clinical stage agreement
contracts since 2003 available in the public domain, respectively. Each
chapter is organized by A-Z, therapeutic area, and deal type. Each deal title
links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in pre-clinical stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs
to know about pre-clinical stage partnering, enabling thorough learning,
education and due diligence prior and during the pre-clinical stage dealmaking
process.
Key benefits
Pre-clinical Stage Partnering Agreements in Biopharma provides the reader with the following key benefits:
- In-depth understanding of pre-clinical stage partnering deal trends since
2000
- Analysis of the structure of pre-clinical stage partnering agreements with
numerous real life case studies
- Comprehensive access to over 800 actual pre-clinical stage partnering
contracts entered into by the world' s biopharma companies*
- Detailed access to actual pre-clinical stage partnering contracts enter
into by the leading fifty bigpharma companies*
- Insight into the payment and deal terms included in a pre-clinical stage
partnering agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Report scope
Pre-clinical Stage Partnering Agreements in Biopharma is intended to provide
the reader with an in-depth understanding of the pre-clinical stage partnering
trends and structure of deals entered into by leading biopharma companies
worldwide.
Pre-clinical Stage Partnering Agreements in Biopharma includes:
- Trends in pre-clinical stage partnering dealmaking in the biopharma
industry since 2000
- Analysis of pre-clinical stage partnering deal structure
- Average payment terms for pre-clinical stage deals
- Case studies of real-life pre-clinical stage partnering deals
- Access to over 1000 pre-clinical stage partnering contract documents
- The leading pre-clinical stage partnering deals by value since 2000
- Most active pre-clinical stage partnering dealmakers since 2000
- The leading pre-clinical stage partnering resources
In Pre-clinical Stage Partnering Agreements in Biopharma, the available contracts are listed by:
- A-Z
- Headline value
- Therapeutic area
- Deal type
Each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
| 
View Cart
